Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Ablify (Aripiprazole) – US: CAFC clarifies differences between obviousness and obviousness-type double patenting for chemical composition-of-matter invention: Otsuka v Sandoz (Patent Docs) (Patently-O)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Is the WHO CEWG proposal for the R&D treaty “too small”? (KEI)

Draft proposal calls for delay of WHO R&D treaty talks (IP Watch)

Full agenda for WHO: reform, R&D convention, substandard medicines, NCDs, pandemics (IP Watch)

More notes on the USTR 2012 Special 301 List (KEI)

Self-replicating technologies (Patently-O)

Canada: Provinces express concern over CETA IP provisions impact on prescription drug prices (Michael Geist)

Germany: German Ministry advises developing countries not to sign ACTA over concerns regarding its impact on seeds and medicines (IP Watch)

India: Compulsory licensing: pot vs kettle – US response to India compulsory license issue (Spicy IP)

UK: Medeva: the final chapter in the UK – EWCA applies CJEU Medeva ruling and dismisses appeal (The SPC Blog)

US: Prometheus based patent reexamination requests? (Patents Post-Grant)

US: Patent-eligible subject matter after Mayo v. Prometheus: Exploring the path forward (BIOtechNOW)

US: US: Enzo Life Sciences files patent infringement complaint against Siemens Healthcare based on their nucleic acid array products (Patent Docs)

US: Senate HELP subcommittee hearings on S.1138, the HIV/AIDS prize fund (KEI)

US: American Invents Act strategies highlighted at the BIO IPCC Conference (BIOtechNOW)

US: Updated House Energy & Commerce UFA Bill would shorten FDA’s 505(q) petition response timeframe; require timely responses to RLD withdrawal petitions (FDA Law Blog)

US: GAO Report says that FDA has met most PDUFA performance goals; Agency plans to take steps to address lingering stakeholder concerns (FDA Law Blog)

 

Products

Ablify (Aripiprazole) – US: CAFC clarifies differences between obviousness and obviousness-type double patenting for chemical composition-of-matter invention: Otsuka v Sandoz (Patent Docs) (Patently-O)

Coenzyme Q10 – US: ALJ Rogers denies motion for summary determination in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)

Coenzyme Q10 – US: ALJ Rogers grants motion to strike expert report in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)

Coversyl (Perindopril) – UK: EWCA: Comity and ex turpi causa: Servier v Apotex (IPKat)

Hectorol (Doxercalciferol) – US: Genzyme files patent infringement suit against Cobrek in response to Para IV certification (Patent Docs)

Heparin – US: CAFC affirms BPAI sustaining invalidity of application directed to chemically fractured and modified heparin: In re Mousa (Patent Docs)

Melatonin – EU: Neurim and “first authorisation” – the Advocate General speaks: C-130/11 Neurim Pharmaceuticals (The SPC Blog)

OxyContin (Oxycodone) – US: Purdue files patent infringement suit against Watson in response to Para IV certification (Patent Docs)

Plavix (Clopidogrel) – France: Paris Court of First Instance declares non-infringement of EP 0 881 901 in Merckle v Sanofi Aventis (EPLAW)

Renvela (Sevelamer) – US: Genzyme files patent infringement suit against Invagen in response to Para IV challenge (Patent Docs)

Rivastigmine – France: Cour d’Appel upholds preliminary injunction: Novartis v Mylan (Kluwer Patent Blog)

Tarceva (Erlotinib) – US District Court rules Tarceva patent valid: impact on India – OSI v Mylan (Spicy IP)

Univasc (Moexipril) – US: Apotex files patent infringement suits against Mylan, Pfizer, Lupin, UCB and Paddock Laboratories based on the manufacture of Moexipril (Patent Docs)